Medicines/Products by Categories

(Rs. In Lakhs)

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER ENDED 30th JUNE, 2005

 

PARTICULARS

For the Quarter

Ended on 30.06.2005

For the Quarter

Ended on 30.06.2004

For the Year

Ended

31.03.2005

 

 

UNAUDITED

UNAUDITED

UNAUDITED

1

INCOME FROM OPERATIONS

6938.16

5802.02

24662.24

2

OTHER INCOME

10.74

11.99

1159.21

 

TOTAL INCOME

6948.90

5814.01

25821.45

3

TOTAL EXPENDITURE

6154.92

5204.97

21792.86

 

- DECREASE IN STOCK IN TRADE

263.75

291.68

1094.47

 

- CONSUMPTION OF RAW   MATERIAL

4987.44

4080.13

17359.44

 

- STAFF COST

226.17

184.38

725.89

 

- OTHER EXPENSES

677.56

648.78

2613.06

4

INTEREST

196.82

154.03

682.68

5

DEPRECIATION

31.52

24.62

112.92

6

PROFIT BEFORE TAX

565.64

430.39

3232.99

7

- PROVISION FOR TAX

42.41

32.28

163.97

 

- PROVISION FOR DEFERRED TAX

2.50

1.04

257.00

8

NET PROFIT

520.73

397.07

2812.02

9

PAID UP EQUITY SHARE CAPITAL (FACE VALUE OF RS 2/- PER SHARE)*

*727.57

502.5

727.57

10

RESERVES EXCLUDING REVALUATION RESERVES

 

 

 

11

EPS - Rs. NOT ANNUALISED

(PAR VALUE RS 2/-PER SHARE)*

*1.43

7.90

45.98

12
AGGREGATE OF NON-PROMOTERS SHAREHOLDING

 

 

 

 

NUMBER OF SHARES

23791475

3339443

4758295

 

% OF SHARE HOLDING

65.40

66.46

65.40

NOTES:
1. During the Quarter ended on 30.06.2005 the net profit of the company rose by 31.14% and sales rose by 19.58% as compared to corresponding period of previous year.

2. The Company’s expansion plans involving setting up of new finished dosage facility in Jammu, a new 100% Export Oriented Unit at Lalru (Punjab) and a new facility at Baddi for the Domestic Market is at advance stage ,of completion and is expected to be operational in next 2-3 months.

3. The company had received ¬¬¬5 complaints during the quarter under review which were duly redressed to the satisfaction of the shareholders during the same quarter and as such, there were no pending complains as on 30th June 2005.

4. The company is exclusively in the pharmaceutical business segment.

5. The above financial results were taken on record by the Board in its meeting held on
30th July 2005.

 
On behalf of the Board
 
Sd/-
 
Dated: 30.07.2005
 
(Gopal Munjal)
 
Place: Chandigarh
 
Chairman


Terms of use Copyright © 2005. All rights reserved